ClinicalTrials.gov record
Completed Phase 3 Interventional

Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

ClinicalTrials.gov ID: NCT00143156

Public ClinicalTrials.gov record NCT00143156. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 10:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Study identification

NCT ID
NCT00143156
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
450 participants

Conditions and interventions

Interventions

  • pregabalin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2005
Primary completion
Not listed
Completion
Apr 30, 2007
Last update posted
Jan 21, 2021

2005 – 2007

United States locations

U.S. sites
53
U.S. states
26
U.S. cities
47
Facility City State ZIP Site status
Pfizer Investigational Site Tuscaloosa Alabama 35406
Pfizer Investigational Site Phoenix Arizona 85023
Pfizer Investigational Site Little Rock Arkansas 72205
Pfizer Investigational Site La Mesa California 91942
Pfizer Investigational Site Los Gatos California 95032-3739
Pfizer Investigational Site Northridge California 91325
Pfizer Investigational Site Tustin California 92780
Pfizer Investigational Site Walnut Creek California 94598
Pfizer Investigational Site Boulder Colorado 80304
Pfizer Investigational Site Wheat Ridge Colorado 80033
Pfizer Investigational Site New Haven Connecticut 06510
Pfizer Investigational Site Clearwater Florida 33761
Pfizer Investigational Site Hollywood Florida 33021
Pfizer Investigational Site Ocala Florida 34471
Pfizer Investigational Site Tampa Florida 33606
Pfizer Investigational Site West Palm Beach Florida 33407-2450
Pfizer Investigational Site Atlanta Georgia 30303
Pfizer Investigational Site Atlanta Georgia 30309
Pfizer Investigational Site Atlanta Georgia 30327
Pfizer Investigational Site Decatur Georgia 30033
Pfizer Investigational Site Chicago Illinois 60610
Pfizer Investigational Site Chicago Illinois 60612
Pfizer Investigational Site Peoria Illinois 61602
Pfizer Investigational Site Springfield Illinois 62704
Pfizer Investigational Site Indianapolis Indiana 46250
Pfizer Investigational Site Lexington Kentucky 40503
Pfizer Investigational Site Baltimore Maryland 21204
Pfizer Investigational Site Boston Massachusetts 02115
Pfizer Investigational Site Boston Massachusetts 02215
Pfizer Investigational Site Springfield Massachusetts 01104
Pfizer Investigational Site Jackson Mississippi 39202
Pfizer Investigational Site Tupelo Mississippi 38803-4087
Pfizer Investigational Site Jefferson City Missouri 65109
Pfizer Investigational Site St Louis Missouri 63141
Pfizer Investigational Site Omaha Nebraska 68116-6465
Pfizer Investigational Site Englewood New Jersey 07631
Pfizer Investigational Site Shrewsbury New Jersey 07702
Pfizer Investigational Site New Hyde Park New York 11042
Pfizer Investigational Site New York New York 10022-1009
Pfizer Investigational Site New York New York 10032
Pfizer Investigational Site Kettering Ohio 45429
Pfizer Investigational Site Toledo Ohio 43623
Pfizer Investigational Site Tulsa Oklahoma 74104-5428
Pfizer Investigational Site Warwick Rhode Island 02886
Pfizer Investigational Site Memphis Tennessee 38119
Pfizer Investigational Site Dallas Texas 75390-8858
Pfizer Investigational Site Frisco Texas 75034
Pfizer Investigational Site Houston Texas 77030
Pfizer Investigational Site San Antonio Texas 78207
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Salt Lake City Utah 84108
Pfizer Investigational Site Burlington Vermont 05401
Pfizer Investigational Site Charlottesville Virginia 22908

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00143156, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 21, 2021 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00143156 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →